Pieris Pharmaceuticals Has Achieved An Undisclosed Milestone Payment From Boston Pharmaceuticals Based On Dosing The First Patient In A Boston Pharmaceutical-Sponsored Phase 1/2 Study Of BOS-342 (Formerly PRS-342)
Pieris Pharmaceuticals Has Achieved An Undisclosed Milestone Payment From Boston Pharmaceuticals Based On Dosing The First Patient In A Boston Pharmaceutical-Sponsored Phase 1/2 Study Of BOS-342 (Formerly PRS-342)
Pieris Pharmicals 已获得波士顿制药公司一笔未公开的里程碑式付款，该款项基于给药波士顿制药公司赞助的 BOS-342（前身为 PRS-342）的第 1/2 期研究中的第一位患者的给药
Pieris Pharmaceuticals Has Achieved An Undisclosed Milestone Payment From Boston Pharmaceuticals Based On Dosing The First Patient In A Boston Pharmaceutical-Sponsored Phase 1/2 Study Of BOS-342 (Formerly PRS-342)
Pieris Pharmicals 已获得波士顿制药公司一笔未公开的里程碑式付款，该款项基于给药波士顿制药公司赞助的 BOS-342（前身为 PRS-342）的第 1/2 期研究中的第一位患者的给药